• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

"Sales Up, Profits Down": Which Drugmakers Are Failing to Cash In?

양현우 기자

yhw@fntimes.com

기사입력 : 2025-11-07 10:19

◇ Chong Kun Dang increases R&D investment, sales rise but profits fall
◇ Green Cross achieves record quarterly sales... profitability slowdown remains challenge
◇ Yuhan Corp., Korea United Pharm affected by royalties and drug price cuts

Illustration = Gemini & Claude

Illustration = Gemini & Claude

이미지 확대보기
[Korea Financial Times, Yang Hyunwoo] Domestic pharmaceutical companies including Chong Kun Dang, Green Cross, and Korea United Pharm succeeded in expanding their external growth in Q3 this year but saw profitability deteriorate. Yuhan Corporation recorded poor performance with both sales and operating profit declining. Increased research and development (R&D) costs, drug price cuts, and absence of royalties are analyzed to have had an impact.

According to the industry on the 6th, Chong Kun Dang's Q3 separate basis sales increased 4.6% year-over-year to KRW 427.4 billion. However, operating profit during this period decreased 18.7% to KRW 20.5 billion.

The company explained, "Sales increased as existing products such as Godex, Telmitrend, and Imotun, along with new products including Nurapec and Stivarga, grew evenly," adding, "Operating profit decreased due to increased research and development investment."

Chong Kun Dang's cumulative sales for Q3 this year were KRW 1.256 trillion and operating profit was KRW 55.5 billion. Compared to the same period last year, sales increased 9.5% but operating profit decreased 30.9%. Additionally, the company's R&D expenses increased 23.2% year-over-year to KRW 83.1 billion as of the first half of this year.

Green Cross saw its Q3 consolidated sales increase 31.1% year-over-year to KRW 609.5 billion. This is the first time the company has recorded sales exceeding KRW 600 billion on a quarterly basis. The company analyzed that Alyglo growth and expanded prescription drug sales were key to achieving record quarterly sales.

However, operating profit during the same period fell 26.3% to KRW 29.2 billion. The company explained this was due to external environment changes for some high-margin products. Influenza vaccines switched to trivalent vaccines starting this year, and Hunterase showed a slight decrease due to concentrated overseas supply in the first half.

Despite deteriorating profitability, Hunterase's cumulative Q3 sales reached 96% of last year's annual sales. Accordingly, it is projected to achieve double-digit growth on an annual basis.

Korea United Pharm also recorded sales of KRW 74.3 billion in Q3 this year, up 4.3% year-over-year. However, operating profit decreased 16.9% year-over-year to KRW 12.5 billion. A Korea United Pharm official mentioned, "Drug price cuts and demand slowdown due to economic recession affected profitability."

Some companies saw declines in both sales and operating profit. Yuhan Corporation's Q3 sales decreased 5.8% year-over-year to KRW 551.1 billion, and operating profit fell 55.7% to KRW 24.1 billion. Yuhan Corporation cited decreased royalty income from non-small cell lung cancer treatment Lazertinib (Leclaza) as the reason for poor performance.

The company transferred Lazertinib (Leclaza)'s global commercialization rights to Janssen for KRW 1.4 trillion in 2018. Janssen developed a combination therapy using Lazertinib (Leclaza) with its own anticancer drug Rybrevant, receiving approval from the U.S. Food and Drug Administration (FDA) in August last year.

Yuhan Corporation received KRW 80 billion in Lazertinib (Leclaza) technology royalties in Q3 last year and KRW 20.7 billion in Q2 this year. However, there was no royalty inflow in Q3 this year.

While royalty income decreased, overseas business sales increased 92.7% year-over-year to KRW 135.0 billion. The company is currently strengthening its overseas business revenue structure by continuing its active pharmaceutical ingredient (API) supply contract for human immunodeficiency virus (HIV) treatments with global big pharma Gilead.

A Yuhan Corporation official stated, "We expect Q4 performance to be driven by R&D achievements including receipt of $45 million from Lazertinib (Leclaza)'s commercialization in China, and high growth in the overseas business division."

Yang Hyunwoo (yhw@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 LS Cable & System Unit Gaon Cable Turns Exporter as AI Boom Lifts Nine-Month Sales Abroad Past Last Year’s Total Editor’s Note: As investment in artificial intelligence (AI) data centers and power grids grows, the wire and cable industry is drawing attention. LS Cable & System is strengthening the competitiveness of its subsidiaries and accelerating its push into global markets. Gaon Cable is transforming itself into an export-driven company, centered on the North American market, while its U.S. production unit LSCUS is expanding on the back of power demand from AI data centers. LS Marine Solution and LS Eco Energy are also securing new growth engines through submarine cables and operations in Vietn 2 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 3 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 서울에서 떠나는 6000년 시간여행, 강동선사문화축제
[카드뉴스] 강감찬을 만나는 가을, 낙성대로!
[카드뉴스] 새우젓 따라 만나는 옛 마포나루
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시

FT도서

더보기